Allarity Therapeutics Q3 net loss of $5M; cash at $3.9M; substantial doubt about going concern

Allarity Therapeutics, Inc.

Cash $3.9M as of Sept 30, 2022, down from $19.6M at Dec 31, 2021.
Net loss of $5.0M in Q3 2022 vs $1.4M in Q3 2021; R&D expense rose to $3.0M.
Cash insufficient to fund operations beyond Dec 31, 2022; going concern warning issued.
In discussions with Series A preferred holder for bridge loan; no assurance of success.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allarity Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $5.0 million.

Period: the third quarter ended September 30, 2022
Net income: $5.0 million
Result: reported results

Exact text from the filing

Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-072851

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.